Treatment with sevelamer decreases bicarbonate levels in peritoneal dialysis patients [6]

Peritoneal Dialysis International

Volumn 22, Issue 6, 2002, Pages 737-738

  Borras M ^a   Marco, M P ^a   Fernandez E ^a  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; BICARBONATE; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER;

ACIDOSIS; ANALYSIS OF VARIANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSATE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HEMODIALYSIS PATIENT; HUMAN; LETTER; PERITONEAL DIALYSIS; PRIORITY JOURNAL;

EID: 0036873932     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080202200622     Document Type: Letter

References (4)

1. Bleyer AK, Burke SSK, Dillon M. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999; 33:694-701.
2. Gallieni M, Cozzolino M, Brancaccio D. Transient decrease of serum bicarbonate levels with sevelamer hydrochloride as the phosphate binder. Kidney Int 2000; 57:1776-7.
3. Marco MP, Muray S, Betriu A, Craver L, Belart M, Fernández E. Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients. Nephron 2002; 92:499-500.
4. Kleinpeter MA. Spectrum of complications related to secondary hyperparathyroidism in a peritoneal dialysis patient. Adv Perit Dial 2000; 16:286-90.